Emcure Pharmaceuticals, led by Namita Thapar, made a strong debut on the NSE, listing at a 31% premium. This impressive start highlights investor confidence in the company's future prospects. Emcure's IPO was highly anticipated, and its strong market entry reflects its robust business model and growth potential. The company's successful listing is a significant milestone, showcasing the market's positive sentiment and trust in Emcure's leadership and strategic vision